Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
29 03 2021
Historique:
received: 23 05 2020
accepted: 24 07 2020
pubmed: 30 7 2020
medline: 11 2 2022
entrez: 30 7 2020
Statut: ppublish

Résumé

Human respiratory syncytial virus (HRSV) constitutes one the main causes of respiratory infection in neonates and infants worldwide. Transcriptome analysis of clinical samples using high-throughput technologies remains an important tool to better understand virus-host complex interactions in the real-life setting but also to identify new diagnosis/prognosis markers or therapeutics targets. A major challenge when exploiting clinical samples such as nasal swabs, washes, or bronchoalveolar lavages is the poor quantity and integrity of nucleic acids. In this study, we applied a tailored transcriptomics workflow to exploit nasal wash samples from children who tested positive for HRSV. Our analysis revealed a characteristic immune signature as a direct reflection of HRSV pathogenesis and highlighted putative biomarkers of interest such as IP-10, TMEM190, MCEMP1, and TIMM23.

Identifiants

pubmed: 32726438
pii: 5877957
doi: 10.1093/infdis/jiaa468
pmc: PMC8006426
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1052-1061

Subventions

Organisme : CIHR
ID : 229733
Pays : Canada
Organisme : CIHR
ID : 230187
Pays : Canada

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Clin Exp Immunol. 2005 Jun;140(3):470-7
pubmed: 15932508
J Transl Med. 2015 May 07;13:148
pubmed: 25947625
Sci Rep. 2019 Aug 7;9(1):11493
pubmed: 31391513
J Virol. 2012 May;86(10):5422-36
pubmed: 22398282
J Immunol. 2002 Mar 15;168(6):2944-52
pubmed: 11884466
Int J Mol Sci. 2017 Dec 07;18(12):
pubmed: 29215596
Clin Microbiol Rev. 2017 Apr;30(2):481-502
pubmed: 28179378
J Virol. 2020 Jan 6;94(2):
pubmed: 31694949
Front Immunol. 2019 Mar 26;10:566
pubmed: 30972063
PLoS One. 2017 Sep 14;12(9):e0184113
pubmed: 28910318
Expert Rev Mol Diagn. 2017 Jan;17(1):95-103
pubmed: 27917695
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Acta Virol. 2018;62(3):310-325
pubmed: 30160147
Oncol Rep. 2018 Nov;40(5):3092-3101
pubmed: 30132566
Respir Res. 2016 Nov 21;17(1):156
pubmed: 27871304
PLoS One. 2017 Sep 6;12(9):e0184318
pubmed: 28877226
Front Immunol. 2019 Jan 29;10:60
pubmed: 30761132
Curr Top Microbiol Immunol. 2013;372:39-57
pubmed: 24362683
BMC Genomics. 2012 Feb 29;13:82
pubmed: 22375630
Eur J Immunol. 2004 Jun;34(6):1673-9
pubmed: 15162437
Am J Respir Cell Mol Biol. 2006 Feb;34(2):192-203
pubmed: 16210696
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Proc Am Thorac Soc. 2005;2(2):147-9
pubmed: 16113483
Genome Biol. 2003;4(5):P3
pubmed: 12734009
J Virol. 2018 Oct 12;92(21):
pubmed: 30111569
Crit Care. 2012 Aug 16;16(4):R157
pubmed: 22898401
Stroke. 2016 Mar;47(3):652-8
pubmed: 26846866
PLoS Med. 2013 Nov;10(11):e1001549
pubmed: 24265599
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Sci Rep. 2016 Nov 11;6:36603
pubmed: 27833115
J Infect Dis. 2005 Apr 15;191(8):1225-32
pubmed: 15776367
Immunity. 1997 Aug;7(2):273-82
pubmed: 9285411
Cell. 2003 Dec 26;115(7):787-98
pubmed: 14697198
PLoS One. 2015 Jul 10;10(7):e0131927
pubmed: 26162090
PLoS One. 2015 Aug 05;10(8):e0132743
pubmed: 26244642
J Infect Dis. 2017 Dec 27;217(1):134-146
pubmed: 29029245
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
PLoS Pathog. 2013 Jan;9(1):e1003057
pubmed: 23326226
BMC Genomics. 2010 May 31;11:344
pubmed: 20509979
Am J Respir Cell Mol Biol. 2004 Jun;30(6):893-900
pubmed: 14722224
J Gen Virol. 2018 Apr;99(4):489-500
pubmed: 29504924
PLoS One. 2011;6(6):e21461
pubmed: 21731757
Immunol Allergy Clin North Am. 2019 Aug;39(3):361-376
pubmed: 31284926
Front Immunol. 2019 Sep 12;10:2152
pubmed: 31572372
Clin Microbiol Rev. 2017 Jan;30(1):277-319
pubmed: 27903593
Cell Host Microbe. 2009 Sep 17;6(3):207-17
pubmed: 19664979
Hum Vaccin Immunother. 2018 Mar 4;14(3):744-749
pubmed: 29135343
Sci Rep. 2015 Mar 11;5:9012
pubmed: 25757571

Auteurs

Claire Nicolas De Lamballerie (C)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.
Viroscan3D SAS, Lyon, France.

Andrés Pizzorno (A)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.

Julia Dubois (J)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.

Blandine Padey (B)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.

Thomas Julien (T)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.
VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Aurélien Traversier (A)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.

Julie Carbonneau (J)

Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec City, Quebec, Canada.

Elody Orcel (E)

Viroscan3D SAS, Lyon, France.

Bruno Lina (B)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.

Marie-Eve Hamelin (ME)

Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec City, Quebec, Canada.

Magali Roche (M)

Viroscan3D SAS, Lyon, France.

Julien Textoris (J)

Pathophysiology of Injury-Induced Immunosuppression, Hospices Civils de Lyon, bioMérieux, Université Claude Bernard Lyon 1, Hôpital Edouard Herriot, Lyon, France.

Guy Boivin (G)

Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec City, Quebec, Canada.

Catherine Legras-Lachuer (C)

Viroscan3D SAS, Lyon, France.
Ecologie Microbienne, UMR CNRS 5557, USC INRA 1364, Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne, France.

Olivier Terrier (O)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.

Manuel Rosa-Calatrava (M)

CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France.
VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH